Evidence map›Paper›PMID 28193398›Full record

ArticleThe Lancet. Global health2017

Incidence of invasive salmonella disease in sub-Saharan Africa: a multicentre population-based surveillance study.

Florian Marks, Vera von Kalckreuth, Peter Aaby, Yaw Adu-Sarkodie, Muna Ahmed El Tayeb, Mohammad Ali, Abraham Aseffa, Stephen Baker, Holly M Biggs, Morten Bjerregaard-Andersen and 49 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in The Lancet. Global health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 191 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
191citing papers in PubMed, 13 pooled it
42.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

191 citing papers in PubMed, 13 syntheses or guidelines pooled it, 304 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Occurrence of Typhoid Fever Complications and Their Relation to Duration of Illness Preceding Hospitalization: A Systematic Literature Review and Meta-analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
    Pooled it
  9. A Systematic Review of Typhoid Fever Occurrence in Africa.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
    Pooled it
  10. Global Typhoid Fever Incidence: A Systematic Review and Meta-analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
    Pooled it
  11. Prevalence and Serotype Diversity ofFrontiers in veterinary science · 2019
    Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021
    Trial
  18. Trial
  19. Article
  20. Measles Without Rash During Acute Febrile Illness Surveillance in Tanzania, 2023-2024.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article

131 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

59 authors at 20 institutions in 18 countries.

Florian MarksInternational Vaccine Institute, SNU Research Park, Seoul, South Korea. Electronic address: fmarks@ivi.int.
Vera von KalckreuthInternational Vaccine Institute, SNU Research Park, Seoul, South Korea.
Peter AabyBandim Health Project, Bissau, Guinea-Bissau; Research Center for Vitamins and Vaccines, Copenhagen, Denmark.
Yaw Adu-SarkodieKumasi Centre for Collaborative Research in Tropical Medicine, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Muna Ahmed El TayebFaculty of Medicine, University of Gezira, Wad Medani, Sudan.
Mohammad AliJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Abraham AseffaArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Stephen BakerOxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.
Holly M BiggsKilimanjaro Christian Medical Centre, Moshi, Tanzania; Division of Infectious Diseases and International Health, Duke University Medical Center, Durham, NC, USA.
Morten Bjerregaard-AndersenBandim Health Project, Bissau, Guinea-Bissau; Research Center for Vitamins and Vaccines, Copenhagen, Denmark.
Robert F BreimanCenters for Disease Control and Prevention, Nairobi, Kenya; Global Health Institute, Emory University, Atlanta, GA, USA.
James I CampbellOxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.
Leonard CosmasCenters for Disease Control and Prevention, Nairobi, Kenya; WHO-Kenya Country Office, Nairobi, Kenya.
John A CrumpKilimanjaro Christian Medical Centre, Moshi, Tanzania; Division of Infectious Diseases and International Health, Duke University Medical Center, Durham, NC, USA; Duke Global Health Institute, Duke University, Durham, NC, USA; Centre for International Health, University of Otago, Dunedin, New Zealand.
Ligia Maria Cruz EspinozaInternational Vaccine Institute, SNU Research Park, Seoul, South Korea.
Jessica Fung DeerinInternational Vaccine Institute, SNU Research Park, Seoul, South Korea.
Denise Myriam DekkerBernhard Nocht Institute for Tropical Medicine, Hamburg, Germany; German Center for Infection Research, Hamburg-Borstel-Lübeck, Germany.
Barry S FieldsCenters for Disease Control and Prevention, Nairobi, Kenya.
Nagla GasmelseedFaculty of Medicine, University of Gezira, Wad Medani, Sudan; Faculty of Science, University of Hafr Al Batin, Hafr Al Batin, Saudi Arabia.
Julian T HertzKilimanjaro Christian Medical Centre, Moshi, Tanzania; Division of Infectious Diseases and International Health, Duke University Medical Center, Durham, NC, USA.
Nguyen Van Minh HoangOxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.
Justin ImInternational Vaccine Institute, SNU Research Park, Seoul, South Korea.
Anna JaegerBernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Hyon Jin JeonInternational Vaccine Institute, SNU Research Park, Seoul, South Korea.
Leon Parfait KaboreSchiphra Hospital, Ouagadougou, Burkina Faso.
Karen H KeddyNational Institute for Communicable Diseases, Johannesburg, South Africa; Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Frank KoningsInternational Vaccine Institute, SNU Research Park, Seoul, South Korea.
Ralf KrumkampBernhard Nocht Institute for Tropical Medicine, Hamburg, Germany; German Center for Infection Research, Hamburg-Borstel-Lübeck, Germany.
Benedikt LeyInternational Vaccine Institute, SNU Research Park, Seoul, South Korea; Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Australia.
Sandra Valborg LøfbergBandim Health Project, Bissau, Guinea-Bissau; Research Center for Vitamins and Vaccines, Copenhagen, Denmark.
Jürgen MayBernhard Nocht Institute for Tropical Medicine, Hamburg, Germany; German Center for Infection Research, Hamburg-Borstel-Lübeck, Germany.
Christian G MeyerInstitute of Tropical Medicine, Eberhard-Karls University Tübingen, Tübingen, Germany; Duy Tan University, Da Nang, Vietnam.
Eric D MintzNational Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Joel M MontgomeryCenters for Disease Control and Prevention, Nairobi, Kenya.
Aissatou Ahmet NiangInstitute Pasteur de Dakar, Dakar, Senegal.
Chelsea NicholsInternational Vaccine Institute, SNU Research Park, Seoul, South Korea.
Beatrice OlackCenter for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.
Gi Deok PakInternational Vaccine Institute, SNU Research Park, Seoul, South Korea.
Ursula PanznerInternational Vaccine Institute, SNU Research Park, Seoul, South Korea.
Jin Kyung ParkInternational Vaccine Institute, SNU Research Park, Seoul, South Korea.
Se Eun ParkInternational Vaccine Institute, SNU Research Park, Seoul, South Korea.
Henintsoa RabezanaharyLaboratory of Microbiology, University of Antananarivo, Antananarivo, Madagascar.
Raphaël RakotozandrindrainyLaboratory of Microbiology, University of Antananarivo, Antananarivo, Madagascar.
Tiana Mirana RaminosoaLaboratory of Microbiology, University of Antananarivo, Antananarivo, Madagascar.
Tsiriniaina Jean Luco RazafindrabeLaboratory of Microbiology, University of Antananarivo, Antananarivo, Madagascar.
Emmanuel SampoSchiphra Hospital, Ouagadougou, Burkina Faso.
Heidi Schütt-GerowittInternational Vaccine Institute, SNU Research Park, Seoul, South Korea; Institute of Medical Microbiology, University of Cologne, Cologne, Germany.
Amy Gassama SowInstitute Pasteur de Dakar, Dakar, Senegal; University Cheikh Anta Diop de Dakar, Dakar, Senegal.
Nimako SarpongKumasi Centre for Collaborative Research in Tropical Medicine, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana; German Center for Infection Research, Hamburg-Borstel-Lübeck, Germany.
Hye Jin SeoInternational Vaccine Institute, SNU Research Park, Seoul, South Korea.
Arvinda SookaNational Institute for Communicable Diseases, Johannesburg, South Africa.
Abdramane Bassiahi SouraInstitut Supérieur des Sciences de la Population, University of Ouagadougou, Ouagadougou, Burkina Faso.
Adama TallInstitute Pasteur de Dakar, Dakar, Senegal.
Mekonnen TeferiArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Kamala ThriemerInternational Vaccine Institute, SNU Research Park, Seoul, South Korea; Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Australia.
Michelle R WarrenInternational Vaccine Institute, SNU Research Park, Seoul, South Korea.
Biruk YeshitelaArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
John D ClemensInternational Vaccine Institute, SNU Research Park, Seoul, South Korea; International Centre for Diarrheal Disease Research, Bangladesh, Dhaka, Bangladesh; University of California Fielding School of Public Health, Los Angeles, CA, USA.
Thomas F WierzbaInternational Vaccine Institute, SNU Research Park, Seoul, South Korea.
International Vaccine Institute · KRBernhard Nocht Institute for Tropical Medicine · DECenters for Disease Control and Prevention · KEUniversity of Antananarivo · MGArmauer Hansen Research Institute · ETBandim Health Project · GWOxford University Clinical Research Unit · VNDuke Medical Center · USInstitut Pasteur de Dakar · SNUniversity of Gezira · SDCenters for Disease Control and Prevention · USCheikh Anta Diop University · SNGerman Center for Infection Research · DEInternational Centre for Diarrhoeal Disease Research · BDJohns Hopkins University · USKenya Medical Research Institute · KEKilimanjaro Christian Medical Centre · TZKwame Nkrumah University of Science and Technology · GHMenzies School of Health Research · AUNational Institute for Communicable Diseases

Funding

Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5M
Fogarty International Clinical Research Scholars Support Center @ Vanderbilt-AAMCR24TW007988 · FIC · VANDERBILT UNIVERSITY · PI VERMUND, STEN H. · 2007 to 2011
$27.6M
Viral and Host Determinants of HIV-1 TransmissionU01AI067854 · NIAID · DUKE UNIVERSITY · PI HAHN, BEATRICE H · 2005 to 2005
$14.9M
HIV/AIDS Clinical Trials UnitU01AI069484 · NIAID · DUKE UNIVERSITY · PI BARTLETT, JOHN A · 2007 to 2011
$14.6M
International Clinical Trials UnitU01AI062563 · NIAID · DUKE UNIVERSITY · PI BARTLETT, JOHN A · 2004 to 2007
$4.0M
Investigating Febrile Deaths in Tanzania (INDITe)R01AI121378 · NIAID · DUKE UNIVERSITY · PI RUBACH, MATTHEW P · 2016 to 2020
$2.7M
The Impact and Society Ecology of Bacterial Zoonoses in Northern Tanzania: UnderR01TW009237 · FIC · DUKE UNIVERSITY · PI CRUMP, JOHN ANDREW · 2011 to 2014
$1.7M
Biotechnology and Biological Sciences Research Council BB/J010367/1Biotechnology and Biological Sciences Research Council BB/L018926/1FIC NIH HHS R01 TW009237FIC NIH HHS R24 TW007988NIAID NIH HHS P30 AI064518NIAID NIH HHS R01 AI121378NIAID NIH HHS U01 AI062563NIAID NIH HHS U01 AI067854NIAID NIH HHS U01 AI069484Wellcome TrustWorld Health Organization 001
6 · The paper itself

Abstract

backgroundAvailable incidence data for invasive salmonella disease in sub-Saharan Africa are scarce. Standardised, multicountry data are required to better understand the nature and burden of disease in Africa. We aimed to measure the adjusted incidence estimates of typhoid fever and invasive non-typhoidal salmonella (iNTS) disease in sub-Saharan Africa, and the antimicrobial susceptibility profiles of the causative agents.

methodsWe established a systematic, standardised surveillance of blood culture-based febrile illness in 13 African sentinel sites with previous reports of typhoid fever: Burkina Faso (two sites), Ethiopia, Ghana, Guinea-Bissau, Kenya, Madagascar (two sites), Senegal, South Africa, Sudan, and Tanzania (two sites). We used census data and health-care records to define study catchment areas and populations. Eligible participants were either inpatients or outpatients who resided within the catchment area and presented with tympanic (≥38·0°C) or axillary temperature (≥37·5°C). Inpatients with a reported history of fever for 72 h or longer were excluded. We also implemented a health-care utilisation survey in a sample of households randomly selected from each study area to investigate health-seeking behaviour in cases of self-reported fever lasting less than 3 days. Typhoid fever and iNTS disease incidences were corrected for health-care-seeking behaviour and recruitment.

findingsBetween March 1, 2010, and Jan 31, 2014, 135 Salmonella enterica serotype Typhi (S Typhi) and 94 iNTS isolates were cultured from the blood of 13 431 febrile patients. Salmonella spp accounted for 33% or more of all bacterial pathogens at nine sites. The adjusted incidence rate (AIR) of S Typhi per 100 000 person-years of observation ranged from 0 (95% CI 0-0) in Sudan to 383 (274-535) at one site in Burkina Faso; the AIR of iNTS ranged from 0 in Sudan, Ethiopia, Madagascar (Isotry site), and South Africa to 237 (178-316) at the second site in Burkina Faso. The AIR of iNTS and typhoid fever in individuals younger than 15 years old was typically higher than in those aged 15 years or older. Multidrug-resistant S Typhi was isolated in Ghana, Kenya, and Tanzania (both sites combined), and multidrug-resistant iNTS was isolated in Burkina Faso (both sites combined), Ghana, Kenya, and Guinea-Bissau.

interpretationTyphoid fever and iNTS disease are major causes of invasive bacterial febrile illness in the sampled locations, most commonly affecting children in both low and high population density settings. The development of iNTS vaccines and the introduction of S Typhi conjugate vaccines should be considered for high-incidence settings, such as those identified in this study.

fundingBill & Melinda Gates Foundation.

Indexed as

SalmonellaAdolescentAfrica South of the SaharaChildChild, PreschoolDrug Resistance, MultipleFamily CharacteristicsFemaleFeverHumansIncidenceMaleSalmonella InfectionsTyphoid Fever

Identifiers

PMID28193398
PMCPMC5316558
OpenAlexW2587454028

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.